NCT04553939已完成2 期
Phase II Study of Neoadjuvant Toripalimab in Combination With Gemcitabine Therapy in Cisplatin Ineligible Stage II-IIIB Bladder Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 50
- 试验地点
- 1
- 主要终点
- ORR，objective response rate
研究概览
简要总结
This is a pre-surgical study involving subjects with muscle invasive bladder urothelial cancer, who are candidates for cisplatin ineligible neoadjuvant therapy. It is a one-arm phase II study in single center.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Be willing and able to provide written informed consent for the trial.
- •18-75 years of age on day of signing informed consent.
- •Have histologically confirmed muscle invasive disease of the urinary bladder.
- •Histology must be urothelial carcinoma (transitional cell carcinoma) or urothelial carcinoma with mixed histology/features.
- •Clinical stage II-IIIB and Have a surgical evaluation that documents the plan for multimodality therapy with a consolidative radical cystectomy.
- •ECOG 0-1 and good organ function.
- •cisplatin ineligible.
排除标准
- •A non-surgical approach recommended by the treating urologist due to any reason.
- •Is currently participating in or has participated in a study of an investigational agent or using an investigational device within 28 days prior to study registration.
- •Has a diagnosis of immunodeficiency or received systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to study registration.
- •Has a known additional malignancy that is progressing or required treatment ≤ 48 months of study registration. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, in situ cervical cancer.
- •Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
- •Has an active autoimmune disease requiring systemic treatment.
- •Has known evidence of interstitial lung disease or active, non-infectious pneumonitis.
- •Has an active infection requiring systemic therapy.
- •Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator
- •Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
- •Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment.
- •Has received prior therapy with an anti-PD-1, anti-PD-L1, antibody.
- •Has a known history of Human Immunodeficiency Virus.
- •Has known active Hepatitis B or Hepatitis C.
研究组 & 干预措施
Toripalimab in Combination With Gemcitabine Therapy
Experimental
干预措施: Toripalimab (Drug)
Toripalimab in Combination With Gemcitabine Therapy
Experimental
干预措施: Gemcitabine (Drug)
结局指标
主要结局
ORR，objective response rate
时间窗: 3 years
ORR was defined as the percentage of participants in the analysis population who have a CR (disappearance of all target lesions) or a PR (≥30% decrease in the sum of diameters of target lesions) based upon RECIST 1.1.
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
招募中
2 期
Neoadjuvant Toripalimab in Combination with Gemcitabine and Cisplatin Therapy in Local Advanced Bladder Cancer SubjectsUrinary Bladder CancerNCT04861584Zhujiang Hospital41
已完成
1 期
Neoadjuvant Pembrolizumab in Combination With Gemcitabine Therapy in Cis-eligible/Ineligible UC SubjectsUrothelial CarcinomaBladder CancerNCT02365766Jason R. Brown83
已完成
2 期
Neoadjuvant ABI-007, Carboplatin and Gemcitabine in Locally Advanced Bladder CancerBladder CancerNCT00585689University of Michigan Rogel Cancer Center29
进行中（未招募）
2 期
Pembrolizumab in Muscle-invasive Bladder CancerMuscle Invasive Bladder CarcinomaLocalized CancerUrothelial CarcinomaNCT05406713Matthew Galsky46
已完成
2 期
Neoadjuvant Chemotherapy With Methotrexate, Vinblastine, Adriamycin and Cisplatin (M-VAC) Plus Avastin in Patients With Urothelial CancerBladder CancerNCT00506155M.D. Anderson Cancer Center60